Document:

exhibit
10.12

 

AGREEMENT
BY AND BETWEEN ZANDER THERAPEUTICS, INC. AND ROBIN GASSER

 

 

 

Agreement
made on August 7, 2017 ("Execution Date") by and between Robin B. Gasser ("Consultant"), a natural person
whose address is at 48 Swan Street, Werribee, Victoria, Australia and Zander Therapeutics, Inc. ("Company"), a Nevada
corporation whose address is 4700 Spring Street, St 304, La Mesa, California 91942. Consultant and Company may be referred to
individually as "Party" and collectively as "Parties".

It
is agreed as follows:

 

		1.	SCOPE
                                         OF SERVICES

 

Consultant
shall advise client on various nominal matters regarding veterinary biotechnology for the Company's wholly owned subsidiary Zander
Therapeutics Inc. "Nominal" is defined as periodic conversations in which Consultant is asked for a referral to an appropriate
researcher on a specific topic or input on research data the company is developing. In the event Consultant is requested to provide
research services, such services will be negotiated separately between Consultant and the Company.

		2.	TERM

 

The
Term of this Agreement shall commence on August 17, 2017 and shall expire on August 16, 2018. The term of this Agreement may be
extended by mutual agreement. 

 

		3.	INDEPENDENT
                                         CONTRACTOR

 

The
Parties are independent contractors. Nothing in this Agreement shall be deemed to constitute a partnership or joint venture between
the Parties or constitute any Party to be the agent of the other Party for any purpose.

 

		4.	NON-DISCLOSURE

 

(a) 
All information, whether in oral, written, graphic,
electronic or other form, disclosed by the Company to the Consultant shall be deemed to be "Proprietary Information."
In particular, Proprietary Information includes, without limitation, any trade secrets, confidential information, ideas, inventions
or research and development information; matters of a technical nature, including technology; notes, products, know- how, engineering
or other data (including test data and data files); specifications, processes, techniques, formulae or work-in-process; manufacturing,
planning or marketing procedures, clinical data and regulatory strategies or information; accounting, financial or pricing procedures
or information, budgets or projections, or personnel or salary structure/compensation information; information regarding suppliers,
clients, customers, employees, contractors, investors or investigators of the Company, information which has been designated in
writing as confidential by the Company; programs, procedures (including operating procedures), processes, methods, guidelines,
policies, proposals or contracts; computer software, data bases or programming; and any other information which, if divulged to
a third party, could have an adverse impact on the Company, or on any third party to which it owes a confidentiality obligation.
In addition, "Proprietary Information" includes any of the foregoing relating to

    	 	1	 

     

    

 

the
past, present or future operations, organization, projects, finances, business interests, methodology or affairs of any third
party to which the Company owes a duty of confidentiality including, without limitation, the mere fact that the Company is or
may be working with or for any client.

 

		(b)	The
                                         obligations of confidentiality shall not apply to any Proprietary Information that was
                                         known by the Consultant at the time of disclosure to it by such Company, or that is independently
                                         developed or discovered by the Consultant after disclosure by such Company, without the
                                         aid, application or use of any item of such Company's Proprietary Information, as evidenced
                                         by written records; now, or subsequently becomes, through no act or failure to act on
                                         the part of the Consultant, generally known or available; is disclosed to the Consultant
                                         by a third party authorized to disclose it; or is required by law or by court or administrative
                                         order to be disclosed; provided, that the Consultant shall have first given prompt notice
                                         to such Company of such required disclosure.

		(c)	Consultant
                                         shall exercise due care to prevent the unauthorized use or disclosure of the Company's
                                         Proprietary Information, and shall not, without the Company's prior written consent,
                                         disclose or otherwise make available, directly or indirectly, any item of the Company's
                                         Proprietary Information to any person or entity other than those employees, independent
                                         contractors or agents of the Consultant (collectively, "Representatives"),
                                         to the extent such Representatives reasonably need to know the same in order to evaluate
                                         such Proprietary Information, to participate in the business relationship between the
                                         parties, or to make decisions or render advice in connection therewith. Consultant shall
                                         advise its Representatives who have access to the Company's Proprietary Information of
                                         the confidential and proprietary nature thereof, and agrees that such Representatives
                                         shall be bound by terms of confidentiality and restrictions on use with respect thereto
                                         that are at least as restrictive as the terms of this Agreement.

		(d)	Consultant
                                         shall exercise due care to prevent the unauthorized use or disclosure of the Company's
                                         Proprietary Information, and shall not, without the Company's prior written consent,
                                         disclose or otherwise make available, directly or indirectly, any item of the Company's
                                         Proprietary Information to any person or entity other than those employees, independent
                                         contractors or agents of the Consultant (collectively, "Representatives"),
                                         to the extent such Representatives reasonably need to know the same in order to participate
                                         in any business relationship between the parties, or to make decisions or render advice
                                         in connection therewith. Consultant shall advise its Representatives who have access
                                         to the Company's Proprietary Information of the confidential and proprietary nature thereof,
                                         and agrees that such Representatives shall be bound by terms of confidentiality and restrictions
                                         on use with respect thereto that are at least as restrictive as the terms of this Agreement.

		(e)	Consultant
                                         shall use the Company's Proprietary Information solely for the purposes of performing
                                         his duties pursuant to this Agreement and shall not make any other use of the Company's
                                         Proprietary Information without the Company's specific written authorization.

		(f)	All
                                         Proprietary Information of the Company (including all copies thereof) shall be and at
                                         all times remain the property of such Company, and all non-oral Proprietary Information
                                         of the Company which is then in the Consultant's possession or control shall be destroyed
                                         or returned to the Company promptly upon its request at any time, and in any event, no
                                         later than 60 days following any expiration or termination of this Agreement.

		(g)	Nothing
                                         in this Agreement shall be construed, by implication or otherwise, as a grant of any
                                         right or license to trademarks, inventions, copyrights or patents, as a grant of a license
                                         to either Consultant to use any of the Company's Proprietary Information except as expressly
                                         set forth herein.

    	 	2	 

     

    

		(h)	The
                                         provisions of Section 4 of this Agreement shall survive until such time as all Confidential
                                         Information disclosed hereafter becomes publically known and made generally available
                                         through no action or inaction of Consultant.

 

		5.	CONSIDERATION

 

As
consideration of the performance of services pursuant to this Agreement, Consultant shall receive:

 

		(1)	Within
                                         15 business days of the execution date of this Agreement Consultant shall be issued 500,000
                                         shares of the Zander Therapeutics Inc.'s Series M Preferred Stock of the Company ("Compensation
                                         Shares").

		(2)	Consultant
                                         acknowledges that, in the event that a Zander Registration Statement is filed with the
                                         United States Securities and Exchange Commission ("SEC"), no assurance is given
                                         that the Zander Registration Statement will be declared effective by the SEC.

		(3)	Consultant
                                         acknowledges that any securities issued pursuant to this Agreement that are not registered
                                         pursuant to the Securities Act of 1933 shall constitute "restricted securities"
                                         as that term is defined in Rule 144 promulgated under the Securities Act of 1933, and
                                         shall contain the following restrictive legend:

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT''), OR SECURITIES LAWS OF ANY
STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE
ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY
THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

 

		6.	REPRESENTATIONS
                                         AND WARRANTIES OF COMPANY

 

 (a) Company is a corporation duly organized, validly existing and in good standing under the laws of the state its incorporation and has the requisite corporate power and authority to enter into and perform its obligations under this Agreement without the consent, approval or authorization of, or obligation to notify, any person, entity or governmental agency which consent has not been obtained.

(b) 
The execution, delivery and performance of this
Agreement by Company does not and shall not constitute Company's breach of any statute or regulation or ordinance of any governmental
authority, and shall not conflict with or result in a breach of or default under any of the terms, conditions, or provisions of
any order, writ, injunction, decree, contract, agreement, or instrument to which the Company is a party, or by which Company is
or may be bound.

    	 	3	 

     

    

 

 

		7.	REPRESENTATIONS
                                         AND WARRANTIES OF CONSULTANT

 

		(a)	Consultant
                                         has the requisite power and authority to enter into and perform his obligations under
                                         this Agreement without the consent, approval or authorization of, or obligation to notify,
                                         any person, entity or governmental agency which consent has not been obtained.

 

		(b)	The
                                         execution, delivery and performance of this Agreement by Consultant does not and shall
                                         not constitute Consultant's breach of any statute or regulation or ordinance of any governmental
                                         authority, and shall not conflict with or result in a breach of or default under any
                                         of the terms, conditions, or provisions of any order, writ, injunction, decree, contract,
                                         agreement, or instrument to which the Consultant is a party, or by which Company is or
                                         may be bound.

 

		8.	NON-DISPARAGEMENT

 

Consultant
agrees that Consultant shall not, during the term of this Agreement, disparage the Company, the Company's products, the Company's
employees, or members of the Company's board of directors. For purposes of this Agreement the term "disparage" shall
mean any negative comment, written or oral, about the Company, the Company's products, the Company's employees, or members of
the Company's board of directors.. Nothing set forth in this Agreement shall prohibit or limit in any way a Party's right to accurately
and honestly respond as required or to cooperate with any valid government, court or regulatory order or request. The provisions
of Section 8 of this Agreement shall survive until that date which is three years subsequent to the end of the Term of this Agreement.

 

		9.	WORK
                                         PRODUCT

 

Consultant
agrees that the Company is the sole and exclusive owner of all intellectual property, including copyrights, trademarks, patents,
inventions, work product and know-how, which may result from any work performed by the Consultant pursuant to this Agreement.
Consultant agrees that Consultant shall, upon request of the Company, execute, acknowledge, deliver and file any and all documents
necessary or useful to vest in the Company all of Consultant's right, title and interest in and to all intellectual property,
including copyrights, trademarks, patents, inventions, work product and know-how, which may resuh from any work performed by the
Consultant pursuant to this Agreement. The term "Inventions" means all original works of authorship, developments, concepts,
improvements or trade secrets, whether or not patentable under law, that Consultant may individually or jointly conceive or develop
or reduce to practice, or cause to be conceived or developed or reduced to practice.

 

		10.	SPECIFIC
                                         PERFORMANCE

 

Any
breach of this Agreement may result in irreparable damage to Company for which Company will not have an adequate remedy at law.
Accordingly, in addition to any other remedies and damages available,

    	 	4	 

     

    

Consultant
acknowledges and agrees that Company may immediately seek enforcement of this Agreement by means of specific performance or injunction,
without any requirement to post a bond or other security.

 

 

		11.	EXECUTION

 

This
Agreement may be executed in two or more counterparts, all of which when taken together shall be
considered one and the same Agreement and shall become effective when counterparts have been signed by each party and delivered
to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature
is delivered by facsimile transmission, such signature shall create a valid and binding obligation of the party executing (or
on whose behalf such signature is executed) with the same force and effect as if such facsimile
signature page were an original thereof.

 

		12.	ENTIRE
                                         AGREEMENT

 

 

This
Agreement constitutes a final written expression of all the terms of the Agreement between the parties regarding the subject matter
hereof, are a complete and exclusive statement of those terms, and supersedes all prior and contemporaneous Agreements, understandings,
and representations between the parties.

 

13.   
SEVERABILITY

 

If
any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefore, and upon so agreeing, shall incorporate
such substitute provision in this Agreement

 

14.
GOVERNING LAW, VENUE, WAIVER OF JURY TRIAL

 

All
questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by and construed
and enforced in accordance with the internal laws of the State of California, without regard to the principles of conflicts of
law thereof. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in California
for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or inconvenient venue for such
proceeding. If either party shall

    	 	5	 

     

    

commence
an action
or
proceeding
to
enforce
any
provisions
of this
Agreement,
then
the prevailing
party in such
action
or
proceeding
shall
be reimbursed
by the
other
party for its attorneys' fees
and other
costs and
expenses
incurred
with
the investigation,
preparation
and
prosecution
of such
action
or proceeding.

 

IN
WITNESS WHEREOF
, the
parties hereto
have
caused this
Agreement to be
duly executed
by their
respective authorized
signatories
as of the date
first
indicated
above.

 

	COMPANY	 	CONSULTANT
	 	 	 
	By: Harry Lander, Ph.D.	 	By: Harry Lander
	/s/ Harry Lander	 	/s/ Harry Lander
	 	 	 
	lts: President and CSO	 	 
	Date: August 16, 2017	 	Date: 18th August 2017

 

    	 	6exhibit
10.13 

 

EMPLOYMENT
AGREEMENT BETWEEN

ZANDER
THERAPEUTICS, INC.

AND

Harry
M. Lander, Ph.D., M.B.A.

 

THIS EMPLOYMENT
AGREEMENT (the "Agreement") dated as of August 5, 2017 is entered into between Zanderr Therapeutics,
Inc., a Nevada corporation, (the "Company") and Harry M. Lander ("Employee").

 

WITNESSETH:

WHEREAS, Employee
and the Company desire to enter into an agreement providing for the employment by the Company of Employee
upon the terms provided herein.

REPRESENTATIONS AND WARRANTIES

A)
Company hereby represents and warrants to Employee as follows;

(i)
Corporate Existence of Company. Company:

(a)
is a corporation duly formed, validly existing and in good standing under the laws of the State of Nevada and

(b)
has all requisite power and authority, and has all governmental licenses, authorizations, consents and approvals necessary to
execute and deliver this Agreement and to consummate the transactions contemplated by this Agreement.

 

(ii) No
Conflicts. None of the execution, delivery and performance of this Agreement by Company, or the consummation
or the transactions contemplated hereby and thereby

 

(a)
constitutes or will constitute a violation of the organizational documents of Company,

(b)
constitutes or will constitute a breach or violation of, or a default (or an event which, with notice
or lapse of time or both, would constitute such a default) under, any indenture, mortgage,
deed of Company, loan agreement, lease or other agreement or instrument to which Company is a
party or by which Company or any of its properties may be bound,

(c)
violates or will violate any statute, law or regulation or any order, judgment, decree or injunction of any court
or Governmental Authority directed to Company or any of its properties in a proceeding to which
its property is or was a party.

 

(B)
Employee hereby represents and warrant to Company as follows:

(i)
No Conflicts. None of the execution, delivery and performance of this Agreement by Employee, or the consummation of the transactions
contemplated hereby and thereby

(a)
constitutes or will constitute a breach or violation of, or a default (or an event which, with notice or lapse of time or both,
would constitute such a default) under, any indenture, mortgage, deed of Trust, loan agreement, lease or other agreement or instrument
to which Employee is a party or by which Employee or any of its properties may be bound,

    	 	1	 

     

    

(b)
violates or will violate any statute, law or regulation or any order, judgment, decree or injunction of any court or Governmental
Authority directed to Employee or any of their properties in a proceeding to which its property is or was a party.

AGREEMENT:

NOW,
THEREFORE, in consideration of the foregoing and the mutual promises and agreements set forth herein, the parties hereto, intending
to be legally bound, hereby agree as follows:

1.
Employment. During the Employment Period (as defined in Section 2), the Company hereby employs Employee and Employee hereby accepts
employment.

2.
Term. The Term of this Agreement shall commence on August 15, 2017 and shall expire on August 14, 2019 unless sooner terminated
in accordance with the provisions of Section 6 hereof; provided, however, that the term of this Agreement may be extended by mutual
agreement. The period from the commencement of the term of this Agreement to the date of its expiration or sooner termination
shall be considered to be the “Employment Period" hereunder. AT THE END OF THE EMPLOYMENT PERIOD, THIS AGREEMENT MAY
BE EXTENDED FOR AN ADDITIONAL YEAR BY WRITTEN MUTUAL CONSENT OF THE PARTIES HERETO.

3.
Duties. Employee shall be granted the title of President and Chief Scientific Officer of the Company subject to the authority
of the Company's Chief Executive Officer (the “CEO”). Employee shall perform such duties commensurate with his office
and as directed the CEO such duties to include, but not be limited to:

 

See
Schedule 1.

 

During
the Employment Period, Employee shall perform his duties hereunder in a diligent manner, subject to the provisions of Schedule
1 of this Agreement; devoting such amount of his business time, attention and efforts to the affairs of the Company within the
scope of his employment as is necessary for the proper rendition of such service and shall use his best efforts to promote the
best interests of the Company. Employee's services shall be rendered when and as required by the Board and in accordance with
his instructions, direction and control.

It
is agreed that Employee will only devote such time as to effectively conduct duties and responsibilities associated with this
position pursuant to this Agreement.

4.
Compensation Salary. During the Employment Period, Company shall pay Employee salary at the rate of:

 

		(i)	During
                                         that period commencing August 15, 2017 and ending on the sooner of (a) the expiration
                                         of the Employment Period or (b) the last day of any month during the Employment period
                                         in which the Company shall have sold equity or debt securities generating net cash proceeds
                                         to the Company of Two Million Dollars ($2,000,000) or more (“Capital Raise”)
                                         Employee shall receive from the Company 10,000 shares of the Company's Series M Preferred
                                         stock per month as compensation for Employee’s services pursuant to this Agreement
                                         .

		(ii)	During
                                         the period commencing the first day subsequent to the end of that month in which the
                                         successful completion by the Company of the Capital Raise shall have occurred and ending
                                         upon the expiration of the Employment Period, Company shall pay Employee salary at the
                                         rate of $16,667 per month prorated for any partial employment month ("Salary").
                                         Salary shall be paid on a monthly basis (“Payday”). In the event that Payday
                                         falls on a Saturday, Sunday or holiday, Salary shall be paid on the next business day.
                                         Salary may be paid, at the Company’s sole discretion, either in:

 

    	 	2	 

     

    

(a)
        cash, or

(b)
        10,000 shares of the Company’s Series M Preferred stock (“Stock Payment”)

(c)       Registered
shares of the Company's common stock

 

Employee
acknowledges that any Stock Payments issued pursuant to this Agreement that are not registered pursuant to the Securities
Act of 1933 shall constitute “restricted securities” as that term is defined in Rule 144 promulgated under the Securities
Act of 1933, and shall contain the following restrictive legend:

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

 

The
Company may register any Stock Payment pursuant to the Securities Act of 1933, but is not obligated to do so pursuant to this
Agreement.

 

5.
Benefits.

a.
During the Employment Period, Employee shall be entitled to participation in any profit sharing plan, retirement plan, group life
insurance plan or other insurance plan, medical expense plan, medical and dental insurance and other benefit arrangements maintained
by the Company for its employees generally and, if applicable, their family members. In addition, Employee shall be entitled to
15 days paid vacation (“Vacation”) subject to having given fourteen days prior notice to the Company of Employee’s
intent to Vacation.

b.
       Stock Compensation.  Employee acknowledges he has received 500,000 Series M Preferred
shares that are fully vested and considered compensation in full for service prior to the execution of this agreement .

Employee
acknowledges that any Series M Shares  issued prior to or pursuant to this Agreement will not be  registered pursuant
to the Securities Act of 1933 , shall constitute “restricted securities” as that term is defined in Rule 144 promulgated
under the Securities Act of 1933 and shall contain the following restrictive legend:

THESE
SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR SECURITIES LAWS OF
ANY STATE AND MAY NOT BE OFFERED, SOLD, ASSIGNED, PLEDGED, TRANSFERRED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION
UNDER THE ACT OR SUCH LAWS AND, IF REQUESTED BY THE COMPANY, UPON DELIVERY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO
THE COMPANY THAT THE PROPOSED TRANSFER IS EXEMPT FROM THE ACT OR SUCH LAWS.

d.       Milestone
Shares. Employee shall receive another an aggregate of 10,000,000 newly issued Series M Preferred shares of the Company upon achievement
of milestones (“Milestone Shares”).  The shares shall be subject to a vesting schedule (See Schedule 2)

 

 

6.
Termination.

    	 	3	 

     

    

a.
Employee's employment hereunder shall terminate upon the earlier of:

(i)
the expiration of the Employment Period,

(ii)
the death of Employee,

(iii)
the expiration of a continuous period of thirty (30) calendar days during which Employee is unable to perform his material duties
due to physical or mental incapacity,

(iv)
termination by the Company due to “just cause,”

(v)
termination by Employee due to a material breach of this Agreement by the Company. The exercise of the right of the Company or
Employee to terminate this Agreement pursuant to clauses (iv) or (v) hereof, as the case may be, shall not abrogate the rights
and remedies of the terminating party in respect of the breach giving rise to such termination.

b.
"Just cause" hereunder shall be defined and limited to mean:

(i)
Employee's failure or refusal, as determined by the CEO in his sole discretion, to perform specific directives of the CEO which
are consistent with the scope and nature of Employee's duties and responsibilities as set forth herein (including the duties described
in Section 3), which failure or refusal continues after notice thereof and a reasonable time to cure; such reasonable time to
be determined by the CEO.

(ii)
Employee's conviction for a felony or any crime involving moral turpitude, fraud, or misrepresentation, or the presentation of
proof satisfactory to the CEO in the exercise of his reasonable judgment of Employee's misappropriation or embezzlement of funds
or assets from the Company;

(iii)
any intentional act having the purpose and effect of injuring the reputation, business or business relationships of the Company
in any material respect; and

(iv)
any breach by Employee of any material provision of this Agreement, including, without limitation, the restrictive covenants contained
in Section 7 hereof.

c.
In the event of any dispute regarding the existence of Employee's incapacity hereunder, the matter wil1 be resolved by the determination
of a physician qualified to practice medicine in California selected by the CEO. For this purpose, Employee will submit to appropriate
medical examinations.

d.
If Employee's employment hereunder is terminated pursuant to Section 6, the Company shall have no further obligations or liabilities
hereunder.

7. Restrictive
Covenant.

a.
Non-disclosure. Employee has, and during the Employment Period will have, access to confidential information and trade secrets
of the Company and its subsidiaries (the "Confidential Information") that may include, among other things:

(i)
Financial information

(ii)
Supply and services information

(iii)
Marketing information

    	 	4	 

     

    

(iv)
Personnel information

(v)
Customer information

(vi)
Product information

(vii)
The Company’s procedures, systems, policies and processes of operation.

 

Employee
shall at all times during his employment by the Company and thereafter hold in strictest confidence any and all Confidential Information
that may have come or may come into Employee's possession or within Employee's knowledge. Employee agrees that neither he nor
any person or entity, directly or indirectly, controlled by or under common control with the Employee (an "Affiliate")will
for any reason, except in the course of performing his duties hereunder, for himself or any other person, use or disclose to anyone,
exclusive of Company employees, agents, representatives, or independent consultants to the Company or any of its subsidiaries
or Affiliates of the Company, any Confidential Information; provided, however, that Employee may disclose Confidential Information
which (i) has become generally available to the public other than as a result of a breach of this Agreement by Employee or (ii)
Employee is compelled to disclose pursuant to subpoena or an order by a court competent jurisdiction; provided that, if Employee
is so required to disclose any Confidential Information pursuant to the foregoing clause (ii), Employee shall provide advance
written notice to the Company, to the extent possible, to allow the Company to seek an appropriate protective order therefore
(iii) Potential advisors, employees, or investors of the Company where there is a reasonable expectation of confidentiality. All
Confidential Information shall remain the Company's property and shall be returned (or, at the Company's option, destroyed) upon
the Company's written request.

b.
Non-Solicitation of Employees. Employee agrees that from the date hereof and continuing for a period of three years following
the termination of this Agreement for whatever reason (the "Non-Compete Period"), neither Employee nor any Affiliate
of Employee will solicit or hire for employment any officer, director or employee of the Company who was employed by the Company
at any time within twelve months prior to the act of solicitation.

c.
Non-Competition. Employee agrees that, other than with the approval of the CEO, which approval shall not be unreasonably withheld,
during the Employment Period, neither Employee nor any Affiliate of Employee will, directly or indirectly, become a shareholder,
director, officer, agent, partner or employee of, or otherwise hold any ownership interest in, any person, firm or entity engaged
in any Competitive Business (as defined below), engage as a sole proprietor in any Competitive Business, act as a consultant to
or assist any of the foregoing or otherwise engage or participate in any Competitive Business; provided, however, that the foregoing
shall not prohibit the ownership by Employee of less than ten percent (10%) of the outstanding shares of the stock of any corporation
engaged in any Competitive Business, which shares are regularly traded on a national securities exchange or in any over-the-counter
market. For the purpose hereof, "Competitive Business" means the ownership, operation, development, marketing of the
services related to, or management of cellular therapeutics within the United States.

d.
Consideration, Relief, Reformation; Severability. The Company has specifically bargained for the covenants set forth in this Section
6 in consideration for the compensation, experience, and information that Employee will gain or receive in connection with his
employment by the Company. Employee agrees that the covenants set forth herein will not preclude Employee from engaging in any
lawful profession, trade or business or from being gainfully employed necessary to provide Employee, his family members and dependents
a standard of living to which he and they have been accustomed and may expect. Employee

    	 	5	 

     

    

acknowledges
and agrees that the restrictive covenants in this Section 6 have been specifically negotiated, are reasonable in all respects,
including, without limitation, their geographic scope and duration, and may be enforced by specific performance or otherwise.
Employee shall not raise any issue of reasonableness as a defense in any proceeding to enforce any of such covenants. Notwithstanding
the foregoing, in the event that a covenant included in this Agreement shall be deemed by any court to be unreasonably broad in
any respect, it shall be modified or limited in its geographic scope, duration or otherwise to the extent necessary to make it
reasonable while preserving its restrictive nature to the maximum degree possible and shall be enforced accordingly; provided
however, that if, notwithstanding the foregoing, a court of competent jurisdiction shall hold any of the covenants contained in
Sections 7 (a), (b) or (c) to be unenforceable (as so modified), then the unenforceable covenant shall be deemed eliminated from
the provisions of this Agreement for the purpose of those proceedings to the extent necessary to permit the remaining covenants
to be enforced so that the validity, legality or enforceability of the remaining provisions of this Agreement shall not be affected
thereby.

8.
Developments.

Employee
hereby assigns to the Company his entire right, title and interest in all know how, discoveries and improvements,
customer lists, trade secrets and ideas, writings and copyrightable material, which may be conceived by Employee
or developed or acquired by him during the term of this Agreement, which may pertain directly to the Company's business
and were developed with Company resources. Employee agrees to promptly and fully disclose in writing all such developments. Employee
will, upon the Company's request, execute, acknowledge and deliver to the Company all instruments
and do all other acts which are necessary or desirable to entitle the Company to all rights in the foregoing
and enable the Company to file and prosecute applications for, and to acquire, maintain and enforce all letters, trademark
registrations or copyrights with respect to the foregoing in all countries.

9.
Remedies.

Employee
acknowledges that any material breach of this Agreement will cause irreparable harm to the Company, that such harm will be difficult
if not impossible to ascertain, and that the Company shall be entitled to equitable relief, including injunction, against
any actual or threatened breach hereof, without bond and without liability should such relief be denied, modified or vacated.
Neither the right to obtain such relief nor the obtaining of such relief shall be exclusive of or preclude the
Company from any other remedy.

10.
Legal Counsel.

Employee
acknowledges that Employee has carefully read this Agreement and understands all of the terms hereof and that Employee
has been given the opportunity to discuss this Agreement with Employee's private legal counsel and
has availed himself of that opportunity to the extent Employee wishes to do so.

11. Notices.

All
notices, requests and other communications under this Agreement shall be in writing and shall be deemed to have been received
five business days after having been deposited in the United States Mail and enclosed in a registered or certified post-paid
envelope; one day after having been sent by overnight courier on a business day or otherwise at the open of
business on the next succeeding business day; when personally delivered or sent by facsimile communications equipment
of the sending party on a business day or otherwise at the open of business on the next succeeding business day; and, in
each case, addressed to the respective parties at the addresses stated below or to such other changed addresses
that the parties may have fixed by notice in accordance herewith.

    	 	6	 

     

    

If
to the Company:

Zander
Therapeutics, Inc.

4700
Sprint Street, Suite 304

La
Mesa, CA 91942

 

Attn:
David Koos, CEO

 

 

 

If
to Employee:

Harry
M. Lander, Ph.D., M.B.A.

6653
Aranda Ave

La
Jolla, CA 92037

+1(917)
696-1991

hazhml@aol.com

 

12.
Waiver of Breach.

A
waiver by the Company or Employee of a breach of any provision of this Agreement by the other party shall
not operate or be construed as a waiver of any subsequent breach by the other party.

13. Entire
Agreement.

This
instrument contains the entire agreement of the parties with respect to the subject matter hereof and supersedes any
prior agreements of the parties with respect to the subject matter hereof. It may be changed only
by an agreement in writing signed by a party against whom enforcement of any waiver, change,
modification, extension or discharge is sought.

 14.
Applicable Law.

 The
terms and conditions of this Agreement shall be governed by and construed in accordance with the laws of the State or
California. Any action to enforce this Agreement shall be brought in the state courts located in San Diego County, State
of California.

IN
WHITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

By:/s/David
Koos

________________________ 

David
R. Koos

Chief
Executive Officer

 

By: /s/Harry
M. Lander

_________________________

Harry
M. Lander, Ph.D., M.B.A.

 

    	 	7	 

     

    

 

Schedule
1.

 

Employer:
ZanderZander Therapeutics, Inc.

 

Location:
Company Headquarters and any remote offices

 

Description:

 

Job
Description – President

 

Job
Summary

 

The
President, reporting directly to the CEO, will develop a robust strategic plan and vision for the advancement of Zander’s
research into commercial products. The President leads the growth of Zander’s technology, whether from in-house research
or through corporate or academic partnerships, business development, and commercialization initiatives to support Zander’s
vision.

 

He/she
leads the development of the commercial innovation capability at Zander to execute a quantifiable business development strategy
to catalyze the development of new products and services. Zander expects to become a regional leader in moving innovation and
research into the commercial marketplace and will look to the incumbent to play a leading role in realizing that goal. The President
ensures that the research programs of Zander align with that of its vision and plays an important role in external relations.

 

Key
Accountabilities

		•	The
                                         President, in concert with the CEO, will develop a robust strategic plan and vision for
                                         the advancement of ZanderZander’s research into commercial markets. The President
                                         leads the growth of ZanderZander’s technology, business development, and commercialization
                                         initiatives to support ZanderZander’s vision. 

 

		•	The
                                         President will devise an implementation plan that articulates how Zander will achieve
                                         its strategic plan. This will likely include milestones, a catalyst calendar and a plan
                                         for each product line.

 

    	 	8	 

     

    

		•	In
                                         conjunction with the CFO, the President will identify strategies to raise capital to
                                         fund the enterprise. A use of funds document will be created and converted to a 1 and
                                         2 year budget.

 

		•	The
                                         President will be responsible for adjusting and maintaining the ZanderZander Scientific
                                         Advisory Board. In addition to reviewing and revising membership, he/she will organize
                                         quarterly meetings of the SAB and ensure that the materials presented to the SAB are
                                         timely and that any actionable items resulting from the meetings are followed up on.

 

		•	He/she
                                         leads the development of the commercial innovation capability at Zander to execute a
                                         quantifiable business development strategy to catalyze the development of new products
                                         and services. Zander expects to become a regional leader in moving innovation and research
                                         to the commercial marketplace and will look to the incumbent to play a leading role in
                                         realizing that goal. 

 

		•	The
                                         incumbent provides expert intelligence on the biotechnology, pharmaceutical, medical
                                         device, software and intellectual property market dynamics, stays abreast of industry-wide
                                         changes and trends, proactively identifies opportunities for Zander. He/she assesses
                                         the technology transfer and business development needs within ZanderZander’s scientific
                                         & clinical communities, and develops strategies for addressing deficits and advancing
                                         commercialization potential.

 

		•	The
                                         President is responsible for developing and managing external business relationships
                                         with key industry partners (including pharmaceutical, biotechnology, CROs, medical device,
                                         and diagnostic companies), leading commercialization partnerships and new ventures with
                                         industry, including building sponsored research collaborations with industry and academia.
                                         He/she represents Zander at national meetings as needed to further business development
                                         goals. 

 

		•	The
                                         President leads the negotiation and structuring of complex license, collaborative research,
                                         and similar agreements to reflect complex business issues, assessing the protectability
                                         and commercial potential of new invention disclosures, obtaining and maintaining intellectual
                                         property protection through legal counsel, pursuing expanded relationships with the corporate
                                         sector, attracting venture capital (or other funding) for

    	 	9	 

     

    

investment
and facilitating relationships among scientists, industry, research sponsors, patent counsel and university and industry administrators.

 

Schedule
2.

Vesting
Schedule for Milestone shares

		3.	Milestone
                                         Shares will be issued upon occurrence of any of the following events having occurred
                                         during the employment by the Company of the Employee. Milestone shares will vest immediately
                                         and are not subject to Transfer Restrictions.

a)                  
Two Million Milestone Shares will be issued upon the establishment of a Materials Transfer Agreement by and between the Company
and an unaffiliated third party engaged to a material degree in the development , commercialization and marketing of veterinary
pharmaceuticals and/or biologics and which has earned revenues related to sales and /o( licensing of veterinary pharmaceuticals
and/or biologics exceeding $10,000,000 per year during the past three fiscal years immediately prior to the establishment of a
Materials Transfer Agreement with the Company

b)       
Two Million Milestone Shares will be issued upon the granting of a license by the Company ( such license granting the licensee
the right to develop and commercialize intellectual property of the Company and which shall require the payment of royalties to
the Company) to an unaffiliated third party engaged to a material degree in the development , commercialization and marketing
of veterinary pharmaceuticals and/or biologics and which has earned revenues related to sales and /or licensing of veterinary
pharmaceuticals and/or biologics exceeding 10,000,000 per year during the past three fiscal years immediately prior to the granting
of the aforementioned license

c)                  
Two Million Milestone Shares will be issued upon In-licensing by the Company of any optimized compound for veterinary disease
applications

d)                 
Two Million Milestone Shares will be issued upon creation by the Company of an optimized compound for NR2F6 Inhibition

e)                 
Two Million Milestone Shares will be issued upon creation by the Company an optimized compound for NR2F6 Activation

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]